Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Spectral Medical ( (TSE:EDT) ) has shared an update.
Spectral Medical has completed enrollment for its Phase III Tigris trial, which evaluates PMX for endotoxic septic shock, with results expected in August 2025. The company has secured up to US$10 million in funding from Vantive to support PMX commercialization, positioning Spectral closer to potential U.S. FDA approval and market launch, which could significantly impact its operations and market presence.
Spark’s Take on TSE:EDT Stock
According to Spark, TipRanks’ AI Analyst, TSE:EDT is a Neutral.
The overall stock score for Spectral Medical is driven by significant financial challenges and weak valuation metrics. However, positive technical momentum and recent corporate developments in clinical trials and financing provide some optimism. Yet, the financial instability and ongoing inability to achieve profitability weigh heavily on the stock’s outlook.
To see Spark’s full report on TSE:EDT stock, click here.
More about Spectral Medical
Spectral Medical Inc. is a late-stage theranostic company focused on advancing therapeutic options for sepsis and septic shock. The company is engaged in clinical trials and commercialization efforts, particularly for its PMX treatment aimed at addressing endotoxic septic shock.
Average Trading Volume: 72,730
Technical Sentiment Signal: Buy
Current Market Cap: C$236.6M
Find detailed analytics on EDT stock on TipRanks’ Stock Analysis page.